Showing results (291-300 of 353) with videos related to
Sort By:
Pageof 36
Oncoimmunology|September 17, 2025
Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblastsRobert Polten, Ivana Kutle, Jan Lennart Stalp, et al.European Journal of Pharmacology|March 25, 2008
Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonistJohn W Adams, Juan Ramirez, Danny Ortuno, et al.Cell Reports|October 13, 2021
Tracing the emergence of primordial germ cells from bilaminar disc rabbit embryos and pluripotent stem cellsToshihiro Kobayashi, Aracely Castillo-Venzor, Chris A Penfold, et al.BMJ Open|February 7, 2025
Trial protocol of an open-label pilot study of oral naltrexone-bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)Krista J Siefried, Liam Acheson, Brendan Clifford, et al.BMJ Open|July 26, 2022
Iterative delivery of an implementation support package to increase and sustain the routine provision of antenatal care addressing alcohol consumption during pregnancy: study protocol for a stepped-wedge cluster trialEmma Doherty, John Wiggers, Nicole Nathan, et al.The Journal of Pharmacology and Experimental Therapeutics|July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biologyJohn W Adams, Juan Ramirez, Yunqing Shi, et al.Current Cancer Drug Targets|June 21, 2016
Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug ScreeningAmit Sharma, Nidhi Jyotsana, Courteney K Lai, et al.The Journal of Pharmacology and Experimental Therapeutics|February 7, 2008
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterizationWilliam J Thomsen, Andrew J Grottick, Frederique Menzaghi, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 5, 2002
Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999Nancy C Santanello, Drew Baker, Joseph C Cappelleri, et al.Journal of Personalized Medicine|April 3, 2021
Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived MacrophagesDirk Hoffmann, Johanna Sens, Sebastian Brennig, et al.Pageof 36